• Skip to main content
  • Skip to primary sidebar
  • Home
  • News
  • Marketplace
  • Events
  • Education
  • Interviews
    • Career spotlight
  • Opinion
    • Professional Dilemmas
    • Patient perspective
  • PIPcast
  • Jobs

Pharmacy in Practice

EDX/20/1154
Date of prep: December 2020

Prescribing information and
adverse events reporting

For healthcare professionals only

Working group to consider barriers to controlled drug research

13th April 2020 by PIP editor Leave a Comment

 

The newly formed Advisory Council on the Misuse of Drugs (ACMD) working group has sent out a call for written evidence from researchers about barriers to legitimate research with controlled drugs.

 

The ACMD working group to consider barriers to legitimate research with controlled drugs to help in their formulation of advice to government.

 

The deadline to submit written feedback has been extended to 3 May 2020 because of COVID-19.

 

In the letter from Prof Owen Bowden-Jones Chair of the ACMD and Prof Roger Knaggs ACMD Barriers to Research working group Chair commented:

 

“The ACMD is collecting written evidence from researchers regarding barriers to legitimate research with controlled drugs. We would be grateful for your written feedback in the attached questionnaire as part of this call for evidence by Thursday 9th April 2020.

 

“Further to productive conversations between the ACMD and research community representatives, the ACMD has established a dedicated working group to gather further evidence to consider the barriers to legitimate research with controlled drugs.

 

“We would welcome submissions of evidence from as broad a spectrum of research institutions as possible – and would, therefore, be grateful if you could circulate as widely as possible this call for evidence to other colleagues and relevant stakeholders where possible. We will be using your feedback to assist in formulating advice to Government.

 

“The working group will be focussing initially on research which may have been impeded by legal controls intended to cover synthetic cannabinoids. We will also take any opportunities which present themselves to evaluate the scale of issues for research involving other controlled drugs and barriers to research, more generally.”

 

 

This circular is being shared under the Open Government Copyright licence.

 

 

Share this:

  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to share on Twitter (Opens in new window)
  • Click to share on WhatsApp (Opens in new window)
  • Click to share on Telegram (Opens in new window)
  • Click to email this to a friend (Opens in new window)

Related

Next article  Pharmacy apprenticeships foray fails at first hurdle

Filed Under: COVID-19, News Tagged With: Coronavirus, PIP news

About PIP editor

Pharmacy in Practice is a UK pharmacy publication with its roots in Scotland.

Reader Interactions

Begin the discussion right here Cancel reply

Primary Sidebar

Categories

Pharmacy in Practice member login

 
 
Forgot Password

Browse products in PIP Marketplace

© 2021 · About Pharmacy In Practice · Site mantained by Mike

This site is for healthcare professionals, please confirm you are a healthcare professional to continue.

YES

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
Pharmacy In Practice uses cookies, by continuing to use this site we will assume you are ok with that Find out more.